Star Imaging and Path Lab
STARIMAGINGANDPATHLABLTD NSE
Star Imaging and Path Lab
Healthcare ServicesNSE: STARIMAGINGANDPATHLABLTD BSE: 544482 Healthcare Service Provider
Key Fundamentals
SMEHealthcare Service ProviderHealthcare ServicesMarket Cap
₹141 Cr
Volatility
Moderate
P/E Ratio
7.3
EBITDA
₹33.17 Cr
Return on Equity
33.78%
Debt to Equity
0.18
Book Value
₹66.65
52W High
₹152
52W Low
₹46
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Stock is trading at 1.19 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.1%
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 206 days.
- Working capital days have increased from 95.3 days to 142 days
Growth Rate
Revenue Growth
5.64% lower than
3Y
Net Income Growth
21.69% lower than
3Y
Cash Flow Change
-133% higher than
3Y
ROE
-14.83% lower than
3Y
ROCE
-0.58% lower than
3Y
EBITDA Margin (Avg.)
7.45% lower than
3Y
Quarterly Results
| Particulars | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 43 | 41 | 45 | 43 |
| Expenses | 31 | 24 | 28 | 27 |
| Operating Profit | 12 | 17 | 17 | 16 |
| OPM % | 27% | 41% | 38% | 37% |
| Other Income | 0 | 0 | 0 | 1 |
| Interest | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 3 | 3 | 3 |
| PBT | 8 | 13 | 14 | 13 |
| Tax % | 25% | 26% | 26% | 28% |
| Net Profit | 6 | 10 | 10 | 9 |
| EPS in Rs | 41.4 | 7.19 | 5.77 | 5.3 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 69 | 58 | 79 | 84 | 89 |
| Expenses | 54 | 52 | 55 | 54 | 55 |
| Operating Profit | 15 | 6 | 23 | 29 | 33 |
| OPM % | 21% | 10% | 30% | 35% | 37% |
| Other Income | 0 | 0 | 1 | 0 | 1 |
| Interest | 2 | 2 | 3 | 3 | 2 |
| Depreciation | 4 | 3 | 5 | 5 | 6 |
| PBT | 9 | 1 | 16 | 21 | 26 |
| Tax % | 33% | 35% | 23% | 26% | 27% |
| Net Profit | 6 | 1 | 12 | 16 | 19 |
| EPS in Rs | 41.93 | 3.87 | 82.8 | 11.8 | 11.07 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 14 | 17 |
| Reserves | 17 | 17 | 30 | 34 | 99 |
| Borrowings | 30 | 27 | 31 | 33 | 21 |
| Other Liabilities | 10 | 16 | 20 | 18 | 17 |
| Total Liabilities | 58 | 61 | 82 | 98 | 154 |
| Fixed Assets | 15 | 19 | 22 | 21 | 25 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 43 | 42 | 60 | 77 | 128 |
| Total Assets | 58 | 61 | 82 | 98 | 154 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 14 | 5 | 18 | -6 | 23 |
| Investing | -4 | -7 | -7 | -4 | -13 |
| Financing | -7 | -5 | 2 | 0 | 36 |
| Net Cash Flow | 3 | -7 | 13 | -10 | 46 |
| Free Cash Flow | 10 | -2 | 11 | -10 | 13 |
| CFO/OP | 119 | 95 | 95 | -2 | 91 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 85 | 110 | 152 | 222 | 206 |
| Inventory Days | — | — | — | — | 24 |
| Days Payable | — | — | — | — | 398 |
| Cash Conversion Cycle | 85 | 110 | 152 | 222 | -167 |
| Working Capital Days | 6 | -13 | 23 | 121 | 142 |
| ROCE % | — | 6% | 34% | 35% | 26% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Star Imaging and Path Lab insights
46 extracted metrics + investor summaries across FY22–FY26.
Documents
1
Annual Disclosure Confirming Non-Applicability Pertaining To Fund Raising By Issuance Of Debt Securities By Large Entities
8 May - Company confirms it is not a Large Corporate as of March 31, 2026. 8 May - Company confirms it is not a Large Corporate as of March 31, 2026.
2
Compliances-Reg.24(A)-Annual Secretarial Compliance
24 Apr - Company says Regulation 24A annual secretarial compliance report is not applicable under SME listing rules. 24 Apr - Company says Regulation 24A annual secretarial compliance report is not applicable under SME listing rules.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
24 Apr - Company confirms it is not a Large Corporate; initial debt disclosure not required for FY2026-27. 24 Apr - Company confirms it is not a Large Corporate; initial debt disclosure not required for FY2026-27.
4
Compliances-Reg.24(A)-Annual Secretarial Compliance
14h - Company says Regulation 24A annual secretarial compliance report is not applicable under SME listing rules. 14h - Company says Regulation 24A annual secretarial compliance report is not applicable under SME listing rules.
5
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
11h - Company confirms it is not a Large Corporate; initial debt disclosure not required for FY2026-27. 11h - Company confirms it is not a Large Corporate; initial debt disclosure not required for FY2026-27.
4
Notice Of 22Nd Annual General Meeting (AGM) Of The Company For The Financial Year 2025-26 1 Sept 2026
Intimation
Frequently Asked Questions about Star Imaging and Path Lab
What does Star Imaging and Path Lab Ltd do?
Incorporated in 2004, Star Imaging and Path Lab Limited is a healthcare company providing diagnostic services across a wide range of medical tests.[1]
Where is Star Imaging and Path Lab Ltd (544482) listed?
Star Imaging and Path Lab Ltd trades as STARIMAGINGANDPATHLABLTD on the NSE and under code 544482 on the BSE.
Which sector does Star Imaging and Path Lab Ltd belong to?
Star Imaging and Path Lab Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the market capitalisation of Star Imaging and Path Lab Ltd?
Star Imaging and Path Lab Ltd has a market capitalisation of ₹141.1 Cr, which places it in the Small Cap band.
What is the PE ratio of Star Imaging and Path Lab Ltd?
Star Imaging and Path Lab Ltd trades at a PE ratio of 7.30, against a book value of ₹66.65 per share.
What is the 52-week high and low of Star Imaging and Path Lab Ltd?
Over the last 52 weeks Star Imaging and Path Lab Ltd has traded between ₹46 and ₹152.
What is the Return on Equity (ROE) of Star Imaging and Path Lab Ltd?
Star Imaging and Path Lab Ltd reported a return on equity of 33.78%. Its debt-to-equity ratio is 0.18.
Company Information
Incorporated in 2004, Star Imaging and Path Lab Limited is a healthcare company providing diagnostic services across a wide range of medical tests.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544482.md for Star Imaging and Path Lab Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.